← Back to Search

Monoclonal Antibodies

Depemokimab for Asthma (NIMBLE Trial)

Verified Trial
Phase 3
Research Sponsored by GlaxoSmithKline
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adult and adolescent participants more than or equal to (>=)12 years of age, at the time of signing the informed consent/assent.
Participants who have a documented physician diagnosis of asthma for >=2 years that meets the National Heart, Lung, and Blood Institute guidelines (NHLBI) or Global Initiative for Asthma (GINA) guidelines.
Screening 1 day
Treatment 52 weeks
Follow Up 3 months
Awards & highlights

NIMBLE Trial Summary

This trial will see if a new drug, GSK3511294, is non-inferior to current treatments for severe asthma with an eosinophilic phenotype. All participants will continue their standard of care asthma treatment.

Who is the study for?
Adults and adolescents (12+ years) with severe asthma who've been on medium to high dose inhalers for the past year, plus another controller medication. They must have shown improvement with Mepolizumab or Benralizumab treatments. Not for current/former heavy smokers, those with other lung conditions, cancer in remission <1 year, or certain blood disorders.Check my eligibility
What is being tested?
The trial is testing if Depemokimab (GSK3511294) is as effective as Mepolizumab or Benralizumab in reducing asthma attacks when added to standard care. Participants will either continue their current treatment or switch to Depemokimab while maintaining their usual non-biologic asthma medications.See study design
What are the potential side effects?
Potential side effects may include reactions at the injection site, headaches, fatigue, and possible allergic responses similar to those experienced with other biologic therapies used for asthma.

NIMBLE Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I am 12 years old or older and can consent to participate.
I have been diagnosed with asthma for 2 years or more, according to NHLBI or GINA guidelines.
I've been on mepolizumab or benralizumab for 12 months with significant improvement.
I've been on a medium to high dose asthma inhaler for the past year.
I am currently taking a medication in addition to my inhaled corticosteroid for my condition.
I am using Mepolizumab or Benralizumab.

NIMBLE Trial Timeline

Screening ~ 1 day
Treatment ~ 52 weeks
Follow Up ~3 months
This trial's timeline: 1 day for screening, 52 weeks for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Annualized rate of clinically significant exacerbations over 52 weeks
Secondary outcome measures
Weighted mean change from Baseline in Asthma Control Questionnaire-5 (ACQ-5) score
Weighted mean change from Baseline in St. George's Respiratory Questionnaire (SGRQ) total score
Weighted mean change from Baseline in pre-bronchodilator forced expiratory volume in one second (FEV1)

NIMBLE Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Participants receiving GSK3511294 (Depemokimab) plus placebo matching prior anti-IL-5/5R treatmentExperimental Treatment4 Interventions
Participants will receive GSK3511294 (Depemokimab) plus placebo treatment matching the active comparator (participant's anti-Interleukin-5/ 5 receptor [anti-IL-5/5R] treatment prior to randomization): either placebo matching mepolizumab or placebo matching benralizumab. All participants will continue their non-biologic Baseline SoC asthma treatment throughout the study.
Group II: Participants receiving prior anti-IL-5/5R treatment plus placebo matching GSK3511294 (Depemokimab)Active Control5 Interventions
Participants will receive active comparator (participant's anti-IL-5/5R treatment prior to randomization): either mepolizumab or benralizumab, plus placebo matching GSK3511294 (Depemokimab). All participants will continue their non-biologic Baseline SoC asthma treatment throughout the study.
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 3
Standard of care (SoC)
GSK3511294 (Depemokimab)
Completed Phase 3

Find a Location


Travel, including flights, are covered

Your expenses for travel tickets for this trial will be reimbursed.

Who is running the clinical trial?

Iqvia Pty LtdIndustry Sponsor
108 Previous Clinical Trials
170,308 Total Patients Enrolled
4 Trials studying Asthma
1,459 Patients Enrolled for Asthma
GlaxoSmithKlineLead Sponsor
4,764 Previous Clinical Trials
8,103,149 Total Patients Enrolled
296 Trials studying Asthma
446,658 Patients Enrolled for Asthma
GSK Clinical TrialsStudy DirectorGlaxoSmithKline
3,596 Previous Clinical Trials
6,142,641 Total Patients Enrolled
229 Trials studying Asthma
400,544 Patients Enrolled for Asthma

Media Library

Benralizumab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT04718389 — Phase 3
Asthma Research Study Groups: Participants receiving prior anti-IL-5/5R treatment plus placebo matching GSK3511294 (Depemokimab), Participants receiving GSK3511294 (Depemokimab) plus placebo matching prior anti-IL-5/5R treatment
Asthma Clinical Trial 2023: Benralizumab Highlights & Side Effects. Trial Name: NCT04718389 — Phase 3
Benralizumab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04718389 — Phase 3
Asthma Patient Testimony for trial: Trial Name: NCT04718389 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any still available positions for participants in this experiment?

"The trial is currently ongoing, as seen from the date of the last edit on clinicaltrials.gov. This study was originally posted on 1/26/2021."

Answered by AI

Is this research project happening in more than one place within the city limits?

"At the moment, this clinical trial is looking for participants from 100 different enrolment centres. With locations in Los Angeles, Omaha and Spring - amongst other cities - it might be best to select a site closeby to cut down on travel time if you do decide to participate."

Answered by AI

How many volunteers are helping with this research?

"That is correct, the online clinicaltrial registry shows that 1700 patients are needed for this study which is being conducted at 100 locations."

Answered by AI

What is the efficacy of GSK3511294 (Depemokimab) in other medical trials?

"In 2014, the first trials for GSK3511294 (Depemokimab) were completed at National Institutes of Health Clinical Center. To date, a total of 18314 clinical trials have been concluded. Out of the 35 active studies, many are being conducted in Los Angeles."

Answered by AI

Has Depemokimab been cleared by the FDA?

"GSK3511294 (Depemokimab) has been deemed safe by our team at Power. This is due to Phase 3 trial data which supports both efficacy and safety."

Answered by AI

Is this research the initial of its type?

"GSK3511294 (Depemokimab) has been the focus of 35 ongoing clinical trials in 455 cities across 42 countries. The first study began in 2014 and was completed successfully by AstraZeneca. To date, a total of 18314 studies have been undertaken."

Answered by AI

What medical conditions does GSK3511294 (Depemokimab) address?

"GSK3511294, marketed as Depemokimab, can be used to help patients struggling with hypereosinophilic syndrome (HES), polyangium, and corticosteroid therapy."

Answered by AI

Who else is applying?

What state do they live in?
How old are they?
18 - 65
What site did they apply to?
First Excellent Research Group
GSK Investigational Site
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
How many prior treatments have patients received?

Why did patients apply to this trial?

Mejor estado de salud. I have only used inhaler. Nothing else has worked for me.
PatientReceived no prior treatments
Wanting to help anyway I can be of help. I continue having problems with my asthma.
PatientReceived 1 prior treatment

What questions have other patients asked about this trial?

How much does it pay? How long does it takes? How long is the screening process?
PatientReceived no prior treatments
PatientReceived no prior treatments

How responsive is this trial?

Most responsive sites:
  1. First Excellent Research Group: < 24 hours
  2. GSK Investigational Site: < 48 hours
Typically responds via
Phone Call
Average response time
  • < 2 Days
~222 spots leftby Nov 2024